Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment of Major Depressive Disorder (The RELIANCE-II Study)

NCT04855747 is registered in ClinicalTrials.gov with Levomecor Inc. as lead sponsor.

NCT NCT04855747
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04855747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment of Major Depressive Disorder (The RELIANCE-II Study)
Lead sponsor
Levomecor Inc.
Phase
Phase 3
Overall status
Terminated
Start date
March 30, 2021
Completion date
January 14, 2025
Enrollment
236 (actual)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

depression, major depressive disorder